When Did Mounjaro Come Out in the UK?

When exactly did Mounjaro get approved in the UK?

The MHRA granted Mounjaro a UK marketing authorisation in November 2023, covering its use as a weight-management treatment in adults with a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related health condition. That authorisation followed Eli Lilly's earlier approvals in the US (where the FDA cleared it for type 2 diabetes in 2022 and for obesity separately in late 2023) and in the EU, but the UK licensing decision was made independently by the MHRA. Mounjaro carries a Black Triangle (▼) designation, meaning it is subject to additional monitoring while real-world safety data continue to accumulate.

The six licensed strengths (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg) all arrived as part of that original authorisation. Treatment starts at 2.5 mg because the first pen's job is letting your system adjust, not delivering the full therapeutic effect; titration upward happens in steps guided by the prescriber. You can read more about the medicine's full profile on our Mounjaro overview page.

Private prescriptions in the UK became available through GPhC-registered pharmacies shortly after the MHRA authorisation, while the NHS pathway was still being established. That gap between regulatory approval and NHS access is common with new medicines: NICE appraisals and commissioning decisions take time. For context, tirzepatide's clinical development spanned several years of trials before any country approved it for weight management.

What changed when NICE recommended tirzepatide in December 2024?

NICE published Technology Appraisal 1026 on 23 December 2024, recommending tirzepatide as a cost-effective treatment for the NHS in England, a significant step, because a positive NICE recommendation is what triggers commissioning and NHS availability. The NICE criteria for tirzepatide set the qualifying BMI threshold at 35 or above with at least one weight-related comorbidity, with thresholds 2.5 kg/m² lower for certain ethnic-background groups. NICE also specified that treatment should continue only if a patient achieves at least 5% weight loss after six months at the highest tolerated dose.

NHS England then set out a phased rollout rather than opening access all at once. The first cohort (adults with a BMI of 40 or above and four or more qualifying conditions) became eligible from June 2025. A second cohort (BMI 35 to 39.9 with four or more conditions) opened in June 2026. Further phases are planned through 2027. From April 2026, some GP practices also gained the ability to prescribe tirzepatide under the new GP contract, though participation varies by practice. Full details of the qualifying conditions and eligibility thresholds are on our treatment page.

The NICE appraisal is publicly available at nice.org.uk/guidance/ta1026, and it remains the authoritative source for NHS eligibility criteria. Private eligibility follows the licensed criteria rather than NICE thresholds, so the two routes have different access bars.

How does Mounjaro's timeline compare to earlier weight-loss medicines?

Wegovy (semaglutide, by Novo Nordisk) received its UK marketing authorisation in 2021 and its NICE recommendation in March 2023, roughly two years ahead of Mounjaro's NICE approval. Wegovy operates on a single GLP-1 pathway; Mounjaro adds GIP receptor activity on top, making it a dual agonist and the only medicine of its kind for weight management in the UK. In the SURMOUNT-1 trial, adults taking tirzepatide at 15 mg saw average body-weight reductions of around 20 to 21% over 72 weeks, and the subsequent head-to-head SURMOUNT-5 trial (published in the New England Journal of Medicine in 2025) reported greater average weight loss with tirzepatide than with semaglutide 2.4 mg. That evidence base is part of what shaped the NICE committee's decision.

If you're thinking about whether tirzepatide or semaglutide might suit your situation better, that question is best settled in a clinical conversation rather than by timeline alone. Our page on what to do when you start Mounjaro covers the practical side once treatment begins. People sometimes ask whether Mounjaro is available in pill form, it isn't; the licensed UK format remains the once-weekly KwikPen injection.

Can someone access Mounjaro privately now, before the NHS phases reach them?

Private access is available now through GPhC-registered online pharmacies for adults who meet the licensed criteria, without waiting for an NHS referral or the next rollout cohort. That's the route most people using a service like ours take: a free consultation is reviewed the same day by a GPhC-registered Independent Prescriber, identity and weight are verified, and if treatment is clinically appropriate the prescription is issued and the medicine dispatched the same working day (for orders placed before 12pm, Monday to Friday), arriving the next working day via tracked DPD delivery.

The NHS route remains the right choice for people who qualify and are prepared to wait; private treatment suits those outside current NHS criteria or who prefer not to join a waiting list. Either way, these medicines are prescription-only: a prescriber's assessment, not a checkout, is the gateway. You can find out more about how the NHS access picture is developing on our weight loss overview, or read about getting a Mounjaro prescription through a regulated private pharmacy. If you want to understand what stopping treatment involves, our page on coming off Mounjaro covers that clearly, and when to take each weekly dose is a common practical question answered there too.

Pharmacies dispensing these medicines can be verified on the GPhC register at pharmacyregulation.org/registers, a worthwhile check before supplying any personal or medical information online.